Abstract

The Hyperparathyroidism with Jaw-Tumours syndrome is caused by mutations of the CDC73 gene: it has been suggested that early onset of the disease and high Ca2+ levels may predict the presence of a CDC73 mutation. We searched for large deletions at the CDC73 locus in patients with: HPT-JT (nr 2), atypical adenoma (nr 7) or sporadic parathyroid carcinoma (nr 11) with a specific MLPA and qRT-PCR assays applied on DNA extracted from whole blood. A Medline search in database for all the papers reporting a CDC73 gene mutation, clinical/histological diagnosis, age at onset, Ca2+, PTH levels for familial/sporadic cases was conducted with the aim to possibly identify biochemical/clinical markers predictive, in first diagnosis, of the presence of a CDC73 gene mutation. A novel genomic deletion of the first 10 exons of the CDC73 gene was found in a 3-generation HPT-JT family, confirmed by SNP array analysis. A classification tree built on the published data, showed the highest probability of having a CDC73 mutation in subjects with age at the onset < 41.5 years (44/47 subjects, 93.6%, had the mutation). Whereas the lowest probability was found in subjects with age at the onset ≥ 41.5 years and Ca2+ levels <13.96 mg/dL (7/20 subjects, 35.0%, had the mutation, odds ratio = 27.1, p < 0.001). We report a novel large genomic CDC73 gene deletion identified in an Italian HPT-JT family. Age at onset < 41.5 ys and Ca2+ > 13.96 mg/dL are predictive for the presence of a CDC73 genetic lesion.

Highlights

  • Parathyroid carcinoma (PC) is a rare, aggressive tumour for which, at present, neither effective nor surgical cure is available

  • We searched for large deletions at the CDC73 locus in patients with: hyperparathyroidism-jaw tumor syndrome (HPT-JT), atypical adenoma or sporadic parathyroid carcinoma with a specific Multiple Ligation Probe Assay (MLPA) and qRT-PCR assays applied on DNA extracted from whole blood

  • Up to date the frequency of large genomic deletions of the CDC73 locus was never investigated in selected cohorts of sporadic PC and atypical adenoma, resulted negative for coding mutations

Read more

Summary

Introduction

Parathyroid carcinoma (PC) is a rare, aggressive tumour for which, at present, neither effective nor surgical cure is available. Great effort has been made in search of possible immunohistochemistry (IHC) biomarkers for an ultimate post-surgical diagnosis [7] This diagnostic default reflects on the surgery management, since an accurate first diagnosis would address towards a demolitive (in case of malignancy) or conservative (in case of a benign lesion) approach with a dramatic impact on the patient’s quality of life and long overall survival [4]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call